Mainz Biomed (MYNZ) Competitors $1.57 -0.09 (-5.42%) Closing price 03:56 PM EasternExtended Trading$1.60 +0.03 (+1.97%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MYNZ vs. RVPH, ITRM, KZR, CLSD, ASBP, CASI, PMN, TENX, DARE, and BCABShould you be buying Mainz Biomed stock or one of its competitors? The main competitors of Mainz Biomed include Reviva Pharmaceuticals (RVPH), Iterum Therapeutics (ITRM), Kezar Life Sciences (KZR), Clearside Biomedical (CLSD), Aspire Biopharma (ASBP), CASI Pharmaceuticals (CASI), Promis Neurosciences (PMN), Tenax Therapeutics (TENX), Dare Bioscience (DARE), and BioAtla (BCAB). These companies are all part of the "pharmaceutical products" industry. Mainz Biomed vs. Its Competitors Reviva Pharmaceuticals Iterum Therapeutics Kezar Life Sciences Clearside Biomedical Aspire Biopharma CASI Pharmaceuticals Promis Neurosciences Tenax Therapeutics Dare Bioscience BioAtla Mainz Biomed (NASDAQ:MYNZ) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability. Which has more risk and volatility, MYNZ or RVPH? Mainz Biomed has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. Comparatively, Reviva Pharmaceuticals has a beta of -0.04, indicating that its stock price is 104% less volatile than the S&P 500. Which has stronger earnings and valuation, MYNZ or RVPH? Mainz Biomed has higher revenue and earnings than Reviva Pharmaceuticals. Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMainz Biomed$893.99K8.04-$21.65M-$65.60-0.02Reviva PharmaceuticalsN/AN/A-$29.92M-$0.65-0.66 Does the media favor MYNZ or RVPH? In the previous week, Reviva Pharmaceuticals had 1 more articles in the media than Mainz Biomed. MarketBeat recorded 3 mentions for Reviva Pharmaceuticals and 2 mentions for Mainz Biomed. Mainz Biomed's average media sentiment score of 1.45 beat Reviva Pharmaceuticals' score of 0.59 indicating that Mainz Biomed is being referred to more favorably in the media. Company Overall Sentiment Mainz Biomed Positive Reviva Pharmaceuticals Positive Is MYNZ or RVPH more profitable? Company Net Margins Return on Equity Return on Assets Mainz BiomedN/A N/A N/A Reviva Pharmaceuticals N/A N/A -259.17% Do insiders & institutionals hold more shares of MYNZ or RVPH? 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 18.2% of Mainz Biomed shares are owned by company insiders. Comparatively, 27.2% of Reviva Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts rate MYNZ or RVPH? Mainz Biomed currently has a consensus target price of $14.00, indicating a potential upside of 791.72%. Reviva Pharmaceuticals has a consensus target price of $5.50, indicating a potential upside of 1,179.07%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than Mainz Biomed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Reviva Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 SummaryReviva Pharmaceuticals beats Mainz Biomed on 8 of the 14 factors compared between the two stocks. Get Mainz Biomed News Delivered to You Automatically Sign up to receive the latest news and ratings for MYNZ and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MYNZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYNZ vs. The Competition Export to ExcelMetricMainz BiomedMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.19M$3.11B$5.75B$10.26BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-0.0221.3775.2626.44Price / Sales8.04240.13456.1288.47Price / CashN/A44.4425.8129.91Price / Book0.609.6413.256.27Net Income-$21.65M-$53.20M$3.29B$270.47M7 Day Performance-4.27%0.17%0.68%2.74%1 Month Performance-11.30%3.98%4.54%5.95%1 Year Performance-87.12%9.16%73.36%25.97% Mainz Biomed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYNZMainz Biomed3.2535 of 5 stars$1.57-5.4%$14.00+791.7%-86.4%$7.19M$893.99K-0.0230Short Interest ↓RVPHReviva Pharmaceuticals3.1408 of 5 stars$0.45-2.2%$5.20+1,055.6%-63.1%$30.60MN/A-0.695News CoverageAnalyst ForecastITRMIterum Therapeutics3.006 of 5 stars$0.68-2.2%$9.00+1,229.8%-37.4%$30.22MN/A-0.8010Positive NewsShort Interest ↓Gap UpKZRKezar Life Sciences3.6174 of 5 stars$3.95-0.5%$9.00+127.8%-30.7%$28.93M$7M-0.4160News CoverageAnalyst UpgradeCLSDClearside Biomedical2.3598 of 5 stars$0.37-5.1%$4.20+1,042.9%-98.3%$28.85M$1.66M-0.9930Stock SplitGap DownHigh Trading VolumeASBPAspire BiopharmaN/A$0.58+3.4%N/AN/A$28.49MN/A0.00N/APositive NewsGap UpCASICASI Pharmaceuticals3.7644 of 5 stars$2.31-5.3%$4.00+73.2%-68.2%$28.41M$28.54M-0.80180PMNPromis Neurosciences3.6714 of 5 stars$0.54+2.7%$4.33+702.6%-64.2%$27.97MN/A0.005Positive NewsShort Interest ↓Gap DownTENXTenax Therapeutics2.2571 of 5 stars$5.99+1.0%$17.00+183.8%+60.4%$27.33MN/A-6.519DAREDare Bioscience2.5552 of 5 stars$2.02-0.5%$12.00+494.1%-36.3%$27.23M$10K-0.9430Positive NewsShort Interest ↓BCABBioAtla2.3481 of 5 stars$0.46+8.5%$5.00+997.7%-57.2%$26.75M$11M-0.4160 Related Companies and Tools Related Companies Reviva Pharmaceuticals Alternatives Iterum Therapeutics Alternatives Kezar Life Sciences Alternatives Clearside Biomedical Alternatives Aspire Biopharma Alternatives CASI Pharmaceuticals Alternatives Promis Neurosciences Alternatives Tenax Therapeutics Alternatives Dare Bioscience Alternatives BioAtla Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MYNZ) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mainz Biomed NV Please log in to your account or sign up in order to add this asset to your watchlist. Share Mainz Biomed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MYNZ Stock Alerts